Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

2017 Walk to End Alzheimer’s-Manhattan Oct 28th

October 17, 2017
Oct122017

Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ET

October 12, 2017

Ladenburg Thalmann 2017 Healthcare Conference Sept 26 3:30pm

September 20, 2017
Sep52017

Anavex®Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73

September 5, 2017

CNS Diseases Summit 2017 Sept 11-12

August 24, 2017
Aug72017

Money 1 1120 x 480

Anavex Reports Fiscal Third Quarter 2017 Financial Results

August 7, 2017
Jul202017

Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board

July 20, 2017

2017 Bio International Convention June 19-22

June 16, 2017
Jun52017

Anavex Life Sciences to Present at Jefferies 2017 Global Healthcare Conference

June 5, 2017

Jefferies 2017 Global Healthcare Conference June 6-9

May 30, 2017

Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome − Data Presented at Antiepileptic Drug Trials XIV 2017 Conference

May 22, 2017
May222017

Multiple sclerosis

Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome − Data Presented at Antiepileptic Drug Trials XIV 2017 Conference −

May 22, 2017
1
234567
…89101112…
131415161718192021222324252627282930313233343536373839404142
43

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top